{"id":"W4312114026","doi":"10.1038/s41408-022-00760-z","title":"Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kingston Health Sciences Centre; University of Manitoba; CancerCare Manitoba","funders":"Cilag; Pharmacyclics; Kite Pharma; Canadian Institutes of Health Research; Ipsen; MorphoSys; Associazione Italiana per la Ricerca sul Cancro; Aptitude Health; Cancer Research UK; Ascentage Pharma; BeiGene; Celltrion; Hairy Cell Leukemia Foundation; Adaptive Biotechnologies; Astex Pharmaceuticals; TG Therapeutics; Genentech; Blood Cancer UK; Amicus Therapeutics; Incyte; Pfizer; Biogen; University of Rochester; CancerCare Manitoba Foundation; MEI Pharma; Daiichi-Sankyo; MacroGenics; Sunesis; University of Pittsburgh; National Cancer Institute; Servier; Gilead Sciences; Teva Pharmaceutical Industries; Leukemia and Lymphoma Society; Sanofi; Ipsen Biopharmaceuticals; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; National Institutes of Health; Leukemia and Lymphoma Society of Canada; GlaxoSmithKline","keywords":"Minimal residual disease; Oncology; Medicine; Bone marrow; Internal medicine; Leukemia; Flow cytometry; Hematology; Hairy cell leukemia; Disease; Cancer research; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007997653,0.0004267839,0.001453653,0.0006107761,0.0001106012,0.00005855854,0.0006621773,0.0002232799,0.002960842],"category_scores_gemma":[0.0002964794,0.000356788,0.0004458665,0.0003184224,0.0001150782,0.0001036054,0.0001869094,0.001508115,0.000008642129],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.02682804,"about_ca_system_score_gemma":0.04025908,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003605387,"about_ca_topic_score_gemma":0.0001175252,"domain_scores_codex":[0.9952279,0.0006159568,0.001168698,0.0006108104,0.001882778,0.0004938127],"domain_scores_gemma":[0.9974758,0.0004579244,0.0006848245,0.0006468394,0.000134169,0.0006004308],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003777034,0.002607102,0.0008907922,0.01301445,0.001889317,0.009071021,0.0006882688,0.000434878,0.0000314024,0.00005226619,0.01416187,0.9533816],"study_design_scores_gemma":[0.01904467,0.0005708353,0.0001391697,0.02433733,0.0009616673,0.0008032371,0.0001384932,0.000312048,0.00002759673,0.00004276256,0.9531859,0.0004363258],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006653881,0.9892236,0.000001273524,0.0001011568,0.001781214,0.0006475861,0.0004413215,0.00002000163,0.00112995],"genre_scores_gemma":[0.001048894,0.9955352,0.000133795,0.0001075415,0.002181374,0.000178646,0.0004002547,0.0001035209,0.0003107775],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9529453,"threshold_uncertainty_score":0.9998884,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.100051708671966,"score_gpt":0.4030415436695617,"score_spread":0.3029898349975957,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}